Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, Professor of Medicine at the University of Central Florida, and at Loma Linda University Health, shared a post on LinkedIn:
“Management of toxicities of Sacituzumab Govitecan: review in The Oncologist Journal – We discuss neutropenia (including use of G-CSF), diarrhea, fatigue, and alopecia associated with SG treatment and provide recommendations on their management in real-world settings to maximize clinical benefit for patients – pleased to coauthor from AdventHealth Central Florida with esteemed colleagues.”
Title: Clinical Perspective on Management of Key Adverse Events With Sacituzumab Govitecan
Authors: Sara M Tolaney, Guru P Sonpavde, Paolo Tarantino, Maryam B Lustberg, Hope S Rugo
Read The Full Article at The Oncologist.
More posts featuring Guru Sonpavde.